AIM ImmunoTech's Ampligen drug in combo with Imfinzi shows promise in late-stage pancreatic cancer trial with positive results and tolerability.

AIM ImmunoTech has announced promising preliminary results from a Phase 1b/2 trial of its drug Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. The therapy was well-tolerated, with no severe side effects noted. Notably, two of three patients in the initial group reached the six-month stability assessment. AIM ImmunoTech specializes in treatments for cancer, immune disorders, and viral diseases.

September 19, 2024
4 Articles